Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction.
Knights
Kathleen M
KM
Department of Clinical Pharmacology, Flinders University School of Medicine, Adelaide, Australia. kathie.knights@flinders.edu.au
Bowalgaha
Kushari
K
Miners
John O
JO
D000450:Aldosterone / Q000378:metabolism*; D001667:Binding, Competitive / Q000187:drug effects; D002191:Canrenoic Acid / Q000494:pharmacology; D002192:Canrenone / Q000494:pharmacology*; D004347:Drug Interactions; D014453:Glucuronosyltransferase / Q000037:antagonists & inhibitors*; D006801:Humans; D006923:Hymecromone / Q000031:analogs & derivatives / Q000378:metabolism; D066298:In Vitro Techniques; D007668:Kidney / Q000187:drug effects*; D008861:Microsomes / Q000201:enzymology*; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology*; D013148:Spironolactone / Q000494:pharmacology*
D013148:Spironolactone; D006923:Hymecromone; D000450:Aldosterone; D002192:Canrenone; D002191:Canrenoic Acid; C491474:UGT2B7 protein, human; D014453:Glucuronosyltransferase